Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies

OverviewBalancedalloy voice

Imagine you're a clinician on a busy ward. You grab a coffee, flip open a major journal, and there it is: a big randomized trial in the New England Journal of Medicine or the Lancet. It looks pristine. The methods are tight, and the discussion is careful. You feel safer making a decision for the person in front of you. Richard Smith, who spent years editing at the BMJ, wants you to pause right there. Not to distrust science, but to see the machinery behind what makes it onto that page. His wake-up was this: journals didn't just take money from drug ads. They became dependent on the industry for the very content that confers authority—original trials—and for the revenue streams that follow those trials out into the world. An ad is obvious. You can ignore it. A front-page trial, packaged with a press release and then circulated to clinics as glossy reprints, is different. It wears the journal's credibility like a crown. And that crown, Smith argues, is now part of the marketing apparatus. Here's the shape of that dependency. In the big general journals—Annals of Internal Medicine, the Journal of the American Medical Association, the Lancet, and the New England Journal of Medicine—between two-thirds and three-quarters of randomized trials are funded by industry. The BMJ sits lower, around one-third, partly because it runs more trials outside classic drug comparisons and because North American publishing dynamics tilt the mix. The money doesn't stop at publication. Publishers know that a favorable trial can trigger massive reprint orders that get handed out by sales representatives around the world. Those reprints can bring profit margins on the order of seventy percent for journals, and a company may spend close to one million dollars to print and ship them globally. You can see how that would focus minds. Does the funding matter for outcomes? The pattern is hard to unsee. Back in 1994, Rochon and colleagues looked at fifty-six arthritis trials of nonsteroidal anti-inflammatory drugs, or NSAIDs, funded by the manufacturers. Not one reported results that were unfavorable to the sponsor's product. Fast forward to a two thousand three systematic review that pulled together thirty studies comparing industry-sponsored research to that funded by others. Among the sixteen that examined clinical trials or meta-analyses, thirteen leaned toward the sponsor's preferred outcome. Taken across the set, the industry-funded work was roughly four times more likely to yield favorable results than research with other funding. And when you zoom in on economic evaluations—five in that review—every one favored the company that paid for it. Smith is careful here. He isn't alleging wholesale fakery. In fact, industry-funded trials often meet high technical standards. The bias, he says, gets baked in by asking the right question in the right way. You pick a comparator that's known to be weaker. Or you use a competitor's dose that's a little too high—then your drug looks safer—or a little too low—then yours looks more potent. You power the study so modestly that differences rarely reach significance; when they do, they flatter the sponsor. You load up on endpoints—lots of chances for chance to smile—and then highlight the ones that do. And when you present the results, you talk in relative risks, not absolute risks, because a "fifty percent reduction" can sound miraculous even when the absolute benefit is small. Design is only half the playbook. The rest is publication strategy. The crudest move is to bury negative studies. More sophisticated is to publish the positive results more than once. Multicenter trials are built for this. Different centers, different journals, different angles—each paper technically true to its slice, the overall impression cumulatively rosier. Supplements help too. They're lucrative for publishers, they can be less rigorous, and they're tailor-made for packaging positive findings. Smith points to cases like risperidone and ondansetron to show how these strategies look in practice, where single datasets spawn a family of papers that march the same upbeat message through the literature. Now, you might be thinking: what about peer review? Isn't that the guardrail? Smith's answer is sobering. By the time a manuscript hits a reviewer's desk, the big decisions—the question, the comparator, the dose, the endpoints—are all locked. Reviewers can fix a table. They can't redesign the trial. And editors, even the scrupulous ones, don't see the whole landscape. They don't know what didn't get submitted. They can't reliably spot when two apparently independent papers are recycling the same core data from a multicenter study. They can insist on trial registration and transparency about sponsor roles, and many do. But, as he puts it, they're looking at a single piece of a gigantic and clever marketing jigsaw. The piece can be immaculate. The picture it supports might still be misleading. The economic pressures tilt in the same direction. Editors at big journals increasingly manage budgets. That's new power, and new temptation. Picture this: you're deciding whether to accept a blockbuster trial that, if it lands, could bring in around one hundred thousand dollars in profit from reprints alone. It's December. You're staring at a deficit and a tough personnel decision. Even if you never say it out loud, those numbers breathe down your neck. And remember, the North American market accounts for roughly half of all drug company revenue. A splashy paper in a North American-influenced journal is not just science. It's market-moving. If that sounds cynical, it's not Smith alone. Richard Horton at the Lancet and Marcia Angell at the New England Journal of Medicine have warned for years that medicine is entangled with industry in ways that bend the evidence ecosystem. Smith's point is to show how journals sit in the bend. It's not that editors are villains. It's that incentives work, even on the well-intentioned, and the paths of least resistance happen to run straight through sponsor-friendly design, publication, and dissemination. So what would help? Start with the fixes that many editors have already tried to enforce. Make prospective trial registration mandatory. Demand the protocol up front, and check the endpoints against what shows up in print. Require clear statements of who designed the study, who controlled the data, and who can decide to publish. Make it a condition that the academic investigators, not the sponsor, hold the pen on submission decisions. These are good steps, and they have moved the field. Smith just doesn't think they reach the root. His root cause is reliance—on sponsors for the questions we ask and on reprint-driven income for the survival of journals. To cut that knot, he pushes for more public funding, especially for large head-to-head trials that compare all reasonable treatments for a condition. Those are the comparisons clinicians actually need. They're not glamorous to a company if the outcome could favor a competitor, but they're gold for practice. He also sketches a structural change in how results meet the world. Picture a regulated platform where protocols and outcomes are posted by rule, for every trial, in standardized form. No more waiting to see if a negative study finds a home. No more confusion about which endpoints were primary and which were opportunistic. The journal's role would shift—from being the vessel that publishes the trial to being the place where experts contextualize and critique what's already transparently on the record. That last bit is radical. It means journals would publish fewer original trials. They'd invest more in skeptical synthesis—what does this mean for patients? How do absolute benefits stack against harms?—and less in the one-shot prestige of a single sponsor-built study. It also means money changes hands differently, which is the whole point. If the engine of journal finance is tied to reprints and supplements that make a sponsor look good, you've designed a system that rewards a certain kind of science. Change the engine, and the vehicle steers differently. Let's circle back to where we began: the clinician with the coffee and the trial. None of this means you should toss the paper in the bin. The randomized trial is still the best tool we have for isolating cause and effect in medicine. But it does mean reading with a new checklist in your head. Who chose the comparator and the dose? Are the headline benefits relative or absolute? Is this one of several publications from a multicenter dataset? And, crucially, who decided when this got published and what stayed in the drawer? The data that set off Smith's alarm—two-thirds to three-quarters of trials in the flagship journals funded by industry, all fifty-six of those NSAID trials favorable in nineteen ninety-four, a fourfold tilt toward sponsor-positive outcomes in that two thousand three review—don't prove malfeasance. They chart a landscape where incentives line up with outcomes. That's different, and in some ways harder to fix. Will the structural reforms happen? Some already have, at least in part. Trial registration is now a norm, thanks to pushes from editors and the International Committee of Medical Journal Editors. Transparency about sponsor roles is more common. But the deeper changes—the public funding of big head-to-heads, the regulated platforms that make every protocol and result visible by default, the shift of journals from publishers of trials to critics of them—will take political will and, yes, money. If they come, the payoff isn't just cleaner literature. It's trust. Trust that when you read a sentence like "Drug A reduced hospitalizations," you can see exactly how big the drop was, in absolute numbers, against the right comparator, at the right dose, with every center counted. Trust that negative findings aren't missing, just missing your attention. And trust that the name on the masthead signals not just prestige, but independence. Until then, skepticism is a virtue, not a sneer. Ask the extra question. Look for the absolute risk. And remember that in a system where a paper can also be a product, even immaculate methods can serve the wrong master.

The methods are tight, and the discussion is careful. You feel safer making a decision for the person in front of you. Richard Smith, who spent years editing at the BMJ, wants you to pause right there.

Not to distrust science, but to see the machinery behind what makes it onto that page.

His wake-up was this: journals didn't just take money from drug ads. They became dependent on the industry for the very content that confers authority—original trials—and for the revenue streams that follow those trials out into the world. An ad is obvious.

You can ignore it. A front-page trial, packaged with a press release and then circulated to clinics as glossy reprints, is different. It wears the journal's credibility like a crown. And that crown, Smith argues, is now part of the marketing apparatus.

Here's the shape of that dependency. In the big general journals—Annals of Internal Medicine, the Journal of the American Medical Association, the Lancet, and the New England Journal of Medicine—between two-thirds and three-quarters of randomized trials are funded by industry. The BMJ sits lower, around one-third, partly because it runs more trials outside classic drug comparisons and because North American publishing dynamics tilt the mix.

The money doesn't stop at publication. Publishers know that a favorable trial can trigger massive reprint orders that get handed out by sales representatives around the world. Those reprints can bring profit margins on the order of seventy percent for journals, and a company may spend close to one million dollars to print and ship them globally. You can see how that would focus minds.

Does the funding matter for outcomes? The pattern is hard to unsee. Back in 1994, Rochon and colleagues looked at fifty-six arthritis trials of nonsteroidal anti-inflammatory drugs, or NSAIDs, funded by the manufacturers.

Not one reported results that were unfavorable to the sponsor's product. Fast forward to a two thousand three systematic review that pulled together thirty studies comparing industry-sponsored research to that funded by others. Among the sixteen that examined clinical trials or meta-analyses, thirteen leaned toward the sponsor's preferred outcome.

Taken across the set, the industry-funded work was roughly four times more likely to yield favorable results than research with other funding. And when you zoom in on economic evaluations—five in that review—every one favored the company that paid for it.

Smith is careful here. He isn't alleging wholesale fakery. In fact, industry-funded trials often meet high technical standards.

The bias, he says, gets baked in by asking the right question in the right way. You pick a comparator that's known to be weaker. Or you use a competitor's dose that's a little too high—then your drug looks safer—or a little too low—then yours looks more potent.

You power the study so modestly that differences rarely reach significance; when they do, they flatter the sponsor. You load up on endpoints—lots of chances for chance to smile—and then highlight the ones that do. And when you present the results, you talk in relative risks, not absolute risks, because a "fifty percent reduction" can sound miraculous even when the absolute benefit is small.

Design is only half the playbook. The rest is publication strategy. The crudest move is to bury negative studies.

More sophisticated is to publish the positive results more than once. Multicenter trials are built for this. Different centers, different journals, different angles—each paper technically true to its slice, the overall impression cumulatively rosier.

Supplements help too. They're lucrative for publishers, they can be less rigorous, and they're tailor-made for packaging positive findings. Smith points to cases like risperidone and ondansetron to show how these strategies look in practice, where single datasets spawn a family of papers that march the same upbeat message through the literature.

Now, you might be thinking: what about peer review? Isn't that the guardrail? Smith's answer is sobering.

By the time a manuscript hits a reviewer's desk, the big decisions—the question, the comparator, the dose, the endpoints—are all locked. Reviewers can fix a table. They can't redesign the trial.

And editors, even the scrupulous ones, don't see the whole landscape. They don't know what didn't get submitted. They can't reliably spot when two apparently independent papers are recycling the same core data from a multicenter study.

They can insist on trial registration and transparency about sponsor roles, and many do. But, as he puts it, they're looking at a single piece of a gigantic and clever marketing jigsaw. The piece can be immaculate. The picture it supports might still be misleading.

The economic pressures tilt in the same direction. Editors at big journals increasingly manage budgets. That's new power, and new temptation.

Picture this: you're deciding whether to accept a blockbuster trial that, if it lands, could bring in around one hundred thousand dollars in profit from reprints alone. It's December. You're staring at a deficit and a tough personnel decision.

Even if you never say it out loud, those numbers breathe down your neck. And remember, the North American market accounts for roughly half of all drug company revenue. A splashy paper in a North American-influenced journal is not just science. It's market-moving.

If that sounds cynical, it's not Smith alone. Richard Horton at the Lancet and Marcia Angell at the New England Journal of Medicine have warned for years that medicine is entangled with industry in ways that bend the evidence ecosystem. Smith's point is to show how journals sit in the bend.

It's not that editors are villains. It's that incentives work, even on the well-intentioned, and the paths of least resistance happen to run straight through sponsor-friendly design, publication, and dissemination.

So what would help? Start with the fixes that many editors have already tried to enforce. Make prospective trial registration mandatory.

Demand the protocol up front, and check the endpoints against what shows up in print. Require clear statements of who designed the study, who controlled the data, and who can decide to publish. Make it a condition that the academic investigators, not the sponsor, hold the pen on submission decisions.

These are good steps, and they have moved the field. Smith just doesn't think they reach the root.

His root cause is reliance—on sponsors for the questions we ask and on reprint-driven income for the survival of journals. To cut that knot, he pushes for more public funding, especially for large head-to-head trials that compare all reasonable treatments for a condition. Those are the comparisons clinicians actually need.

They're not glamorous to a company if the outcome could favor a competitor, but they're gold for practice. He also sketches a structural change in how results meet the world. Picture a regulated platform where protocols and outcomes are posted by rule, for every trial, in standardized form.

No more waiting to see if a negative study finds a home. No more confusion about which endpoints were primary and which were opportunistic. The journal's role would shift—from being the vessel that publishes the trial to being the place where experts contextualize and critique what's already transparently on the record.

That last bit is radical. It means journals would publish fewer original trials. They'd invest more in skeptical synthesis—what does this mean for patients?

How do absolute benefits stack against harms?—and less in the one-shot prestige of a single sponsor-built study. It also means money changes hands differently, which is the whole point. If the engine of journal finance is tied to reprints and supplements that make a sponsor look good, you've designed a system that rewards a certain kind of science. Change the engine, and the vehicle steers differently.

Let's circle back to where we began: the clinician with the coffee and the trial. None of this means you should toss the paper in the bin. The randomized trial is still the best tool we have for isolating cause and effect in medicine.

But it does mean reading with a new checklist in your head. Who chose the comparator and the dose? Are the headline benefits relative or absolute?

Is this one of several publications from a multicenter dataset? And, crucially, who decided when this got published and what stayed in the drawer?

The data that set off Smith's alarm—two-thirds to three-quarters of trials in the flagship journals funded by industry, all fifty-six of those NSAID trials favorable in nineteen ninety-four, a fourfold tilt toward sponsor-positive outcomes in that two thousand three review—don't prove malfeasance. They chart a landscape where incentives line up with outcomes. That's different, and in some ways harder to fix.

Will the structural reforms happen? Some already have, at least in part. Trial registration is now a norm, thanks to pushes from editors and the International Committee of Medical Journal Editors.

Transparency about sponsor roles is more common. But the deeper changes—the public funding of big head-to-heads, the regulated platforms that make every protocol and result visible by default, the shift of journals from publishers of trials to critics of them—will take political will and, yes, money.

If they come, the payoff isn't just cleaner literature. It's trust. Trust that when you read a sentence like "Drug A reduced hospitalizations," you can see exactly how big the drop was, in absolute numbers, against the right comparator, at the right dose, with every center counted.

Trust that negative findings aren't missing, just missing your attention. And trust that the name on the masthead signals not just prestige, but independence.

Until then, skepticism is a virtue, not a sneer. Ask the extra question. Look for the absolute risk.

And remember that in a system where a paper can also be a product, even immaculate methods can serve the wrong master.

More in Pharmacology, Toxicology and Pharmaceutics →

Related lectures